Published in Br J Psychiatry on June 01, 2010
Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET. Mol Psychiatry (2012) 1.16
Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. Eur J Nucl Med Mol Imaging (2011) 1.11
An excitatory synapse hypothesis of depression. Trends Neurosci (2015) 1.05
Electroconvulsive therapy alters dopamine signaling in the striatum of non-human primates. Neuropsychopharmacology (2010) 0.95
Assessing the effects of electroconvulsive therapy on cortical excitability by means of transcranial magnetic stimulation and electroencephalography. Brain Topogr (2012) 0.78
Molecular Neurobiology of Depression: PET Findings on the Elusive Correlation with Symptom Severity. Front Psychiatry (2013) 0.76
Serotonin and the mode of action of electroconvulsive therapy. Br J Psychiatry (2010) 0.75
Unilateral ultra-brief pulse electroconvulsive therapy for depression in Parkinson's disease. Acta Neurol Scand (2016) 0.75
Serotonin and brain function: a tale of two receptors. J Psychopharmacol (2017) 0.75
How Electroconvulsive Therapy Works?: Understanding the Neurobiological Mechanisms. Clin Psychopharmacol Neurosci (2017) 0.75
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol (2003) 6.21
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 5.49
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol (2008) 4.16
DCTN1 mutations in Perry syndrome. Nat Genet (2009) 3.87
A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression. J Neurosurg (2011) 3.30
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
An adaptive reflexive processing model of neurocognitive function: supporting evidence from a large scale (n = 100) fMRI study of an auditory oddball task. Neuroimage (2005) 2.60
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain (2005) 2.40
PET performance measurements using the NEMA NU 2-2001 standard. J Nucl Med (2002) 2.06
Task-related default mode network modulation and inhibitory control in ADHD: effects of motivation and methylphenidate. J Child Psychol Psychiatry (2010) 2.05
Does the salience network play a cardinal role in psychosis? An emerging hypothesis of insular dysfunction. J Psychiatry Neurosci (2012) 1.88
Dorsal striatal D2-like receptor availability covaries with sensitivity to positive reinforcement during discrimination learning. J Neurosci (2011) 1.82
[11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease. Brain (2003) 1.70
Resolution modeling in PET imaging: theory, practice, benefits, and pitfalls. Med Phys (2013) 1.69
Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain (2004) 1.65
Aberrant localization of synchronous hemodynamic activity in auditory cortex reliably characterizes schizophrenia. Biol Psychiatry (2004) 1.65
Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. J Affect Disord (2009) 1.64
Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol (2003) 1.64
SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia. Neurogenetics (2013) 1.58
Irrational choice under uncertainty correlates with lower striatal D(2/3) receptor binding in rats. J Neurosci (2012) 1.57
Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry (2010) 1.57
Propofol reduces cognitive impairment after electroconvulsive therapy. J ECT (2004) 1.55
DNAJC13 mutations in Parkinson disease. Hum Mol Genet (2013) 1.54
Neural primacy of the salience processing system in schizophrenia. Neuron (2013) 1.50
Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. Neurology (2013) 1.50
Statistical dynamic image reconstruction in state-of-the-art high-resolution PET. Phys Med Biol (2005) 1.50
Oxcarbazepine in the treatment of bipolar disorder: a review. Can J Psychiatry (2006) 1.50
Clinical guidelines for depressive disorders. Summary of recommendations relevant to family physicians. Can Fam Physician (2003) 1.45
Chronotherapeutics (light and wake therapy) in affective disorders. Psychol Med (2005) 1.42
Clustering of Parkinson disease: shared cause or coincidence? Arch Neurol (2004) 1.42
Antidepressant effects of exercise: evidence for an adult-neurogenesis hypothesis? J Psychiatry Neurosci (2006) 1.41
Aberrant salience network (bilateral insula and anterior cingulate cortex) connectivity during information processing in schizophrenia. Schizophr Res (2010) 1.39
Do the symptoms of bipolar disorder really show seasonal variation? Bipolar Disord (2013) 1.39
NEMA NU 4-2008 comparison of preclinical PET imaging systems. J Nucl Med (2012) 1.38
Recovery and recurrence following a first episode of mania: a systematic review and meta-analysis of prospectively characterized cohorts. J Clin Psychiatry (2015) 1.38
Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res (2002) 1.36
Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction. J Affect Disord (2009) 1.34
Reproducibility of the hemodynamic response to auditory oddball stimuli: a six-week test-retest study. Hum Brain Mapp (2003) 1.31
Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol (2008) 1.30
Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism Relat Disord (2008) 1.29
Accurate event-driven motion compensation in high-resolution PET incorporating scattered and random events. IEEE Trans Med Imaging (2008) 1.29
Effects of motivation and medication on electrophysiological markers of response inhibition in children with attention-deficit/hyperactivity disorder. Biol Psychiatry (2009) 1.28
Leg muscle strength is reduced in Parkinson's disease and relates to the ability to rise from a chair. Mov Disord (2003) 1.28
Toward [18F]-labeled aryltrifluoroborate radiotracers: in vivo positron emission tomography imaging of stable aryltrifluoroborate clearance in mice. J Am Chem Soc (2008) 1.28
Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci (2006) 1.28
Attention orienting dysfunction during salient novel stimulus processing in schizophrenia. Schizophr Res (2005) 1.27
The placebo effect in Parkinson's disease. Trends Neurosci (2002) 1.24
Rostral anterior cingulate cortex dysfunction during error processing in schizophrenia. Brain (2003) 1.24
Arylfluoroborates and alkylfluorosilicates as potential PET imaging agents: high-yielding aqueous biomolecular 18F-labeling. J Am Chem Soc (2005) 1.23
Error-related negativity and correct response negativity in schizophrenia. Clin Neurophysiol (2002) 1.22
Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain (2011) 1.20
Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol (2011) 1.19
The placebo effect in neurological disorders. Lancet Neurol (2002) 1.18
Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. I. Classification, burden and principles of management. J Affect Disord (2009) 1.17
Changes in brain network activity during working memory tasks: a magnetoencephalography study. Neuroimage (2010) 1.15
Aberrant cortical gyrification in schizophrenia: a surface-based morphometry study. J Psychiatry Neurosci (2012) 1.15
Technical performance evaluation of a human brain PET/MRI system. Eur Radiol (2012) 1.14
Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety (2010) 1.14
Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. J Clin Psychiatry (2008) 1.14
The influence of working memory load on phase specific patterns of cortical activity. Brain Res Cogn Brain Res (2004) 1.14
Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments. J Affect Disord (2009) 1.14
Structural correlates of auditory hallucinations in schizophrenia: a meta-analysis. Schizophr Res (2012) 1.13
Temporal lobe abnormalities in semantic processing by criminal psychopaths as revealed by functional magnetic resonance imaging. Psychiatry Res (2004) 1.13
Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies. J Affect Disord (2009) 1.12
Quality of life in bipolar disorder: a review of the literature. Health Qual Life Outcomes (2005) 1.11
Quantitative micro positron emission tomography (PET) imaging for the in vivo determination of pancreatic islet graft survival. Nat Med (2006) 1.10
Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Ann Neurol (2008) 1.10
Functional imaging in Parkinson disease. Neurology (2008) 1.08
Bipolar disorder and quality of life: a patient-centered perspective. Qual Life Res (2006) 1.08
Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol (2007) 1.07
The dopamine-4 receptor gene associated with binge eating and weight gain in women with seasonal affective disorder: an evolutionary perspective. Biol Psychiatry (2004) 1.07
Cyclotron production of (99m)Tc: experimental measurement of the (100)Mo(p,x)(99)Mo, (99m)Tc and (99g)Tc excitation functions from 8 to 18 MeV. Nucl Med Biol (2011) 1.07
Manganese-52 positron emission tomography tracer characterization and initial results in phantoms and in vivo. Med Phys (2013) 1.07
Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2). Mov Disord (2004) 1.06
Placebo mechanisms and reward circuitry: clues from Parkinson's disease. Biol Psychiatry (2004) 1.06
Substituent effects on aryltrifluoroborate solvolysis in water: implications for Suzuki-Miyaura coupling and the design of stable (18)F-labeled aryltrifluoroborates for use in PET imaging. J Org Chem (2008) 1.06
Carbohydrate-appended 2,2'-dipicolylamine metal complexes as potential imaging agents. Inorg Chem (2005) 1.05
The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction. Curr Pharm Des (2012) 1.05